Compare iShares Core US Aggregate Bond ETF (AGG) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
iShares Core US Aggregate Bond ETF vs Quest Diagnostics Inc — how do they compare? iShares Core US Aggregate Bond ETF trades at $98.05, while Quest Diagnostics Inc trades at $207.24 (market cap $23.51B). The key difference: Quest Diagnostics Inc pays a 1.62% dividend while iShares Core US Aggregate Bond ETF pays none, and Quest Diagnostics Inc is trading nearer its 52-week high, iShares Core US Aggregate Bond ETF nearer its low. Which is the better fit depends on your goals.
| AGG | DGX | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $101.40 | $216.02 |
52-Week Low | $97.63 | $166.42 |
Market Cap | — | $23.51B |
Enterprise Value | — | $29.52B |
Dividend Yield | — | 1.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AGG trades at $98.65, up 0.04% on the day, with technical indicators showing a bearish trend from moving averages but a neutral signal from oscillators. The stock faces resistance at $99 and support at $98. Recent corporate actions include scheduled dividends for May and June 2026. Financial ratios are unavailable in the provided data, limiting fundamental analysis.
The outlook remains cautious due to the bearish technical bias and lack of current financial metrics. Key risks include market volatility and interest rate uncertainty. Investors should await updated earnings reports for a clearer fundamental picture before considering positions.
Quest Diagnostics (DGX) trades at $212.38, down 1.55% today but remains near its 52-week high. The stock shows strong fundamental performance with three consecutive quarterly earnings beats and revenue growth to $11.04 billion in 2025. Technical indicators suggest a bullish trend with support at $212 and resistance at $216. Recent positive developments include New York State approval for the Haystack MRD cancer test, expanding market reach.
DGX presents a balanced investment case with solid fundamentals and analyst support, though valuation appears full. The consensus price target of $222.80 offers modest upside. Key risks include healthcare reimbursement pressures and elevated debt levels. Earnings growth and diagnostic service expansion remain primary catalysts for continued performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core US Aggregate Bond ETF
AGG tracks the Bloomberg U.S. Aggregate Bond Index, providing broad exposure to the total U.S. investment-grade bond market. It serves as a core portfolio building block by diversifying across Treasuries, government-related bonds, corporate debt, and mortgage-backed securities.
Read more on AGG →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
